| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 183,20 | 184,00 | 10.07. | |
| 183,20 | 184,00 | 10.07. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 185,60 | 44 | |||
| 184,30 | 15 | |||
| 184,00 | 44 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/56s1.htm [/URL] | ||||
| 59 | 183,20 | |||
| 44 | 181,60 | |||
| 1.023 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.126 | 0,091 | 103 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SARTORIUS STEDIM BIOTECH Aktie jetzt für 0€ handeln | |||||
| 03.07. | Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech | 453 | Dow Jones News | DJ Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year liquidity contract statement... ► Artikel lesen | |
| 01.07. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 393 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 27.06. | Big Pharma kauft weiter Zukunftstechnologien - Warum Milliarden in Zelltherapien fließen und manche Unternehmen vor einem neuen Marktumfeld stehen | Small- & Micro Cap Investment | |||
| 22.06. | JPMORGAN stuft Sartorius Stedim Biotech auf 'Overweight' | 899 | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sartorius Stedim mit einem Kursziel von 260 Euro auf "Overweight" belassen. Insgesamt erwartet Richard Vosser für den Laborausrüster... ► Artikel lesen | |
| 01.06. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 539 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Fr | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.07.2026 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 10.07.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.07.2026.ISIN NameAU000000OPT2 OPTHEA... ► Artikel lesen | |
| Fr | Alamar Biosciences, Inc.: Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer's Biomarker Profiling | GlobeNewswire (Europe) | Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer's disease detection and stagingFREMONT, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences... ► Artikel lesen | |
| Fr | SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma | GlobeNewswire (Europe) | Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative... ► Artikel lesen | |
| Fr | Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal | AFX News | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| Fr | Clearmind Medicine Inc.: Clearmind Medicine Responds to the U.S. Administration's RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative | GlobeNewswire (Europe) | Vancouver, Canada, July 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage a biotech company developing novel, non-hallucinogenic, next-generation, neuroplastogen-derived... ► Artikel lesen |